Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

Summary

The objective of this pilot study is to evaluate the efficacy of adding S-Gboxin to standard RT/TMZ treatment protocols in patients with glioblastoma multiforme (GBM) or midline glioma (DMG), regardless of their mutation status

Timeline

Start

2026-05-20

Primary completion

2027-10-10

Completion

2027-12-10

Outcome

Outcome not reported

Stopped: “The study protocol will be changed”

Drugs

Indications